Evidence map›Paper›PMID 30227232›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2019

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

Amandeep Salhotra, Matthew Mei, Tracey Stiller, Sally Mokhtari, Alex F Herrera, Robert Chen, Leslie Popplewell, Jasmine Zain, Haris Ali, Karamjeet Sandhu and 4 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Amandeep SalhotraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Division of Biostatistics, Department of Information Sciences, City of Hope, Duarte, California.
Matthew MeiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California.
Tracey StillerDivision of Biostatistics, Department of Information Sciences, City of Hope, Duarte, California.
Sally MokhtariDepartment of Clinical Translational Program Development, City of Hope, Duarte, California.
Alex F HerreraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Robert ChenDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Leslie PopplewellDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Jasmine ZainDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Haris AliDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California.
Karamjeet SandhuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California.
Elizabeth BuddeDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California.
Auayporn NademaneeDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Ryotaro NakamuraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, California. Electronic address: rnakamura@coh.org.
City of Hope · US

Funding

City of Hope Core Clinical Center for the Blood and Marrow Transplant Clinical Trials NetworkUG1HL069278 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI RYOTARO NAKAMURA · 2017 to 2026
$2.2M
Blood and Marrow Transplant Clinical Research NetworkU10HL069278 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NAKAMURA, RYOTARO · 2011 to 2016
$1.0M
NHLBI NIH HHS U10 HL069278NHLBI NIH HHS UG1 HL069278
6 · The paper itself

Abstract

The current standard of care for patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) is high-dose conditioning followed by autologous stem cell transplantation (ASCT). For some patients (ie, those with highest-risk disease, insufficient stem cell numbers after mobilization, or bone marrow involvement) allogeneic hematopoietic cell transplantation (alloHCT) offers the potential for cure. However, the majority of patients undergoing alloHCT receive reduced-intensity conditioning as a preparative regimen, and studies assessing outcomes of patients after alloHCT with myeloablative conditioning are limited. In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018. With a median follow-up of 2.6 years (range, 1.0 to 11.2 years), the probabilities of 2-year overall survival and event-free survival were 58.3% (95% confidence interval [CI], 35.0% to 75.8%) and 45.5% (95% CI, 24.4% to 64.3%), respectively. The cumulative incidence of grade II to IV acute GVHD was 45.5% (95% CI, 23.8% to 64.9%), with only 1 patient developing grade IV acute GVHD. However, chronic GVHD was seen in 55% of the patients (n = 12). Of the 22 eligible patients, 2 had undergone previous ASCT and 2 had undergone previous alloHCT. Both patients with previous ASCT developed severe regimen-related toxicity. Patients who underwent alloHCT with chemorefractory disease had lower survival rates, with 1-year OS and EFS of 44.4% and 33.0%, respectively. In conclusion, alloHCT with a BEAM preparative regimen and tacrolimus/sirolimus-based GVHD should be considered as an alternative option for patients with highest-risk lymphoma whose outcomes are expectedly poor after ASCT.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLymphomaTransplantation ConditioningAdolescentAdultAllograftsAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDisease-Free SurvivalFemaleHumansIncidenceMaleMelphalanCarmustineCytarabineMelphalanPodophyllotoxinSirolimusTacrolimusallogeneic hematopoietic stem cell transplantationBEAM conditioningtacrolimus/sirolimus

Identifiers

PMID30227232
PMCPMC6502508
OpenAlexW2891485401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.